Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy

Inclusion Criteria

• •Patients with metastatic colorectal cancer are eligible for this study; colorectal cancer should have been previously confirmed by pathology or cytology; to be eligible for this protocol, patients should be receiving ziv-aflibercept plus FOLFIRI as a standard treatment prior to enrolling on this trial; the number and type of therapy administered prior to enrollment will not affect the ability to enroll on this study
• •Patients should have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• •Patients should have an expected life expectancy of 12 weeks or longer
• •Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
• •To be eligible for this study, patients should already be receiving a standard dose of ziv-aflibercept intravenously over 60 minutes in combination with FOLFIRI chemotherapy every 2 weeks without evidence of progressive disease; treatment on this study can start as early as two weeks from last "off protocol" ziv-aflibercept plus FOLFIRI cycle, granted treatment parameters have been met
• •Total bilirubin \< 1.5 upper limit of normal (ULN)
• •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 ULN unless patient has metastatic disease to the liver in which case \< 5 ULN will be allowed
• •Serum creatinine \< 1.5 ULN
• •Urine protein/creatinine ration (UPCR) =\< 1 or total urinary protein of \< 1 gm/24 hours in the event the UPCR \> 1
• •Systolic blood pressure \< 155 mm mercury and diastolic blood pressure \< 100 mm mercury documented on two separate occasions at least 24 hours apart
• •Platelet counts \>= 75,000/mm\^3
• •Neutrophil count \>= 1500/mm\^3
• •Hemoglobin \>= 9 gm/dl; anemia can be corrected with transfusion to allow eligibility prior to enrollment
• •Hematological tests can be repeated to assess eligibility
• •No unresolved grade 2 or above non-hematological toxicities, with the exception of alopecia or neuropathy
• •All subjects must have the ability to understand and the willingness to sign a written consent